

RECEIVED

U.S.S.N. 08/700,565  
GRUENBERG  
AMENDMENT

JUL 17 2000  
TECH CENTER 1600/2000

*F 1 CMH*  
214. The method of claim 1, wherein density of the cells is at least  $10^9$  cells/liter.—

—215. The method of claim 1, wherein density of the cells is at least  $10^{10}$  cells/liter.—

—216. The method of claim 22, wherein density of the cells is at least  $10^9$  cells/liter.—

—217. The method of claim 22, wherein density of the cells is at least  $10^{10}$  cells/liter.—

Please cancel claims 2, 3, 5, 7, 14, 16, 17, 154 without prejudice or disclaimer.

Please amend claims 1, 8, 22 and 155 as follows:

1. (Amended) A method for selectively stimulating proliferation and differentiation of T lymphoid cells to generate[ generating] a high density of clinically relevant numbers of T lymphoid cells, comprising:

collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;

treating the cells are under conditions whereby ex vivo differentiation of the cells into Th1, Th1-like, Th2-like or Th2 cells is induced; and

contacting, in the absence of exogenous interleukin-2, the material with two or more activating proteins specific for cell surface proteins present on cells in the material and in an amount sufficient to induce ex vivo cell expansion, whereby the cells expand to [clinically relevant numbers at a density of] at least about [ $10^9$ ]  $10^{10}$  cells regulatory cells of one predominant phenotype [ in a volume of about a liter].

U.S.S.N. 08/700,565  
GRUENBERG  
AMENDMENT

F3  
~~8. (Amended) The method of claim 1, wherein the expanded cells are predominantly Th1 or Th2[ or Th3] cells.~~

F4  
~~22. (Twice Amended) A method for generating clinically relevant cell numbers of regulatory T lymphoid cells, comprising:~~

- ~~(a) collecting material containing mononuclear T lymphoid cells from a mammal;~~
- ~~(b) activating the T lymphoid cells to alter their cytokine production profile by causing differentiation of the cells to regulatory cells; and~~
- ~~(c) inducing cell proliferation and expanding the cells under conditions that produce [high cell density of] at least about 10<sup>10</sup> cells/liter [10<sup>9</sup> cells/liter and produce clinically relevant number] of a homogeneous population of regulatory T lymphoid cells.~~

F5  
~~155. (Amended) A method for generating clinically relevant numbers of regulatory T lymphoid cells for autologous cell therapy, comprising:~~

- ~~(a) collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;~~
- ~~(b) treating the cells to induce differentiation of mononuclear cells into regulatory T cells, wherein regulatory T cells are mononuclear cell that have the ability to control or direct an immune response, but do not act directly as effector cells in the response; and~~
- ~~(c) contacting the resulting differentiated cells with [one] two or more activating proteins specific for cell surface proteins present on the cells in an amount sufficient to induce *ex vivo* cell expansion, whereby clinically relevant numbers of regulatory cells for autologous cell therapy are generated.~~

**REMARKS**

A check for the fee for a three month extension of time accompanies this response. Any fee that may be due in connection with this application may be